In ₹ Crore except Per Share Latest Annual	AJANTPHARM FY26	ALKEM FY26	IPCALAB FY26	TORNTPHARM FY26	Peer Average
Valuation — at last close
P/E	40.93×	◆ 26.34×	42.92×	71.29×	46.85× -13%
P/B	9.58×	◆ 4.39×	6.07×	18.39×	9.61× 0%
EV/EBITDA	30.77×	◆ 20.06×	25.24×	38.65×	27.98× +10%
Market Cap	₹43,369 Cr	₹60,612 Cr	₹48,977 Cr	₹1.54L Cr	₹87,942 Cr -51%
Growth
Revenue CAGR 3Y	13.37%	8.25%	◆ 15.60%	13.27%	12.37% +8%
Revenue CAGR 5Y	◆ 13.54%	10.09%	12.22%	11.80%	11.37% +19%
Net Income CAGR 3Y	21.55%	32.67%	◆ 35.20%	19.75%	29.21% -26%
Revenue YoY (latest Q)	24.82%	10.95%	20.76%	◆ 50.79%	27.50% -10%
Net Income YoY (latest Q)	30.89%	-22.00%	◆ 82.18%	-9.64%	16.85% +83%
Profitability
EBITDA Margin	25.58%	20.43%	20.51%	◆ 32.61%	24.52% +4%
Net Income Margin	◆ 19.37%	15.98%	12.27%	15.29%	14.51% +33%
Return on Common Equity	25.39%	17.84%	15.20%	◆ 27.07%	20.04% +27%
Return on Capital Employed	◆ 27.90%	17.59%	16.05%	14.88%	16.17% +73%
Return on Assets	◆ 18.91%	12.19%	9.81%	7.21%	9.74% +94%
Credit & Quality
Total Debt/Equity	◆ 0.05×	0.11×	0.07×	0.84×	0.34× -85%
Interest Coverage	◆ 75.83×	16.32×	20.55×	8.94×	15.27× +397%
Scale — latest FY
Revenue / Total Income	₹5,453 Cr	₹14,712 Cr	₹9,646 Cr	₹13,980 Cr	₹12,780 Cr -57%
Net Income	₹1,056 Cr	₹2,351 Cr	₹1,184 Cr	₹2,138 Cr	₹1,891 Cr -44%
Total Assets	₹6,155 Cr	₹20,873 Cr	₹12,370 Cr	₹44,312 Cr	₹25,852 Cr -76%
EPS	₹84.53	₹192.51	₹44.98	₹63.92	₹100.47 -16%
Book Value per Share	₹361.16	₹1,156.01	₹317.85	₹247.86	₹573.91 -37%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.